To delineate immune mechanisms for limiting asthma development and severity
To delineate immune mechanisms for limiting asthma development and severity
批准号:
MR/R008167/1
负责人:
Chengcan Yao
金额:
$155.44万
依托单位:
依托单位国家:
英国
项目类别:
Fellowship
财政年份:
2018
资助国家:
英国
项目状态:
已结题
起止时间:
2018 至 --
中文摘要
全世界有超过3亿人患有哮喘,每年导致25万人死亡,这导致了巨额的医疗支出。药物(如皮质类固醇)有助于控制哮喘症状和哮喘加重,但一旦停药,其效果会迅速消失。因此,迫切需要研究哮喘发生和加重的发病机制及其调控机制,以便更好地了解哮喘的控制和加重,这将有助于为哮喘的预防和治疗提供新的机会。非类固醇抗炎药(非类固醇抗炎药,如阿司匹林)在全球范围内被广泛用作止痛药和退烧药。这是因为这些药物阻止了一组名为前列腺素(PGs)的脂质的产生,前列腺素(PGs)介导了疼痛反应和发烧。然而,像其他药物一样,非甾体抗炎药也会造成不良反应--例如,最广为人知的是引起肠道出血。我们的团队最近发现了一种以前未知的机制,即为什么使用非类固醇抗炎药会导致肠道出血,并发现脂质介质前列腺素E2在维持肠道屏障动态平衡方面发挥了重要作用。但前列腺素如何对加重的刺激(如过敏原或病原体诱导的过敏性炎症)做出反应尚不清楚。临床和流行病学观察表明,非甾体抗炎药的使用会引发哮喘和肺部炎症的加重,如严重的慢性嗜酸性鼻窦炎合并鼻息肉病,这种疾病被称为非类固醇抗炎药加重的呼吸系统疾病(NERD)。我在这项应用中的目标是发现关于哮喘是如何因过敏物质或药物的刺激而发展和加重,以及如何控制这些用于治疗哮喘和NERD的过敏化学反应的科学事实。最近被证明在动物模型和哮喘患者中被称为2型固有淋巴样细胞(ILC2s)的免疫细胞亚群参与了哮喘的发展和加重。但在哮喘背景下,负面控制ILC2功能的信号仍有待揭示。在CDA应用中,我将使用药理学、免疫学和遗传学方法以及实验模型和通过分析哮喘患者的临床样本来确定前列腺素在预防2型过敏性肺部炎症中的作用和确切的细胞和分子机制。这一连贯的实验组合将有助于剖析患者由于生理前列腺素信号功能障碍而发展为哮喘和NERD的特定致病机制。前列腺素信号在这方面的成功验证将为相关过敏性肺部炎症的治疗提供新的治疗选择。
英文摘要
There are more than 300 million people worldwide living with asthma, and it causes 250,000 deaths annually, which is responsible for huge healthcare expenditure. Drugs (e.g. corticosteroids) help control both asthma symptoms and asthma exacerbations, yet their effects rapidly disappear when discontinued. It is thus urgent to study the pathogenic mechanisms underlying the development and exacerbation of asthma and the regulatory mechanisms for better understanding of the control of asthma and its exacerbation, which will help for providing new opportunities to prevention and treatment of asthma. Non-steroidal anti-inflammatory drugs (NSAIDs such as aspirin) are very commonly used at huge amounts as pain killers and reducing fever worldwide. This is because these drugs block the production of a group of lipids called prostaglandins (PGs) that mediate the pain response and fever generation. Like other drugs, however, NSAIDs can also cause adverse effects - e.g., the most well known one is inducing gut bleeding. Our group has recently discovered a previously unknown mechanism as to why use of NSAIDs leads to bleeding in the gut and found an essential role of the lipid mediator prostaglandin E2 in the maintenance of gut barrier homeostasis. But how prostaglandins function in response to aggravating stimuli (e.g. allergen- or pathogen-induced allergic inflammation) are not well understood. Clinical and epidemiological observations suggest that use of NSAIDs triggers exacerbations of asthma and lung inflammation such as severe chronic eosinophilic rhinosinusitis with nasal polyposis, a condition called as NSAID-exacerbated respiratory disease (NERD). My goal in this application is to discover the scientific facts as to how asthma is developed and exacerbated by stimuli of allergic substances or drugs and how to control these allergic chemical reactions for treatment of asthma and NERD.A subset of immune cells called type 2 innate lymphoid cells (ILC2s) has recently been demonstrated to mediate the development and exacerbation of asthma in both animal models and patients with asthma. But signals that negatively control ILC2 function in the context of asthma remain to be revealed. In this CDA application, I will define the role of prostaglandins in protection against type 2 allergic lung inflammation and the precise cellular and molecular mechanisms using pharmacological, immunological and genetic approaches, as well as experimental models and via analysis of clinical samples from asthma patients. This coherent portfolio of experiments will help dissect the specific pathogenic mechanisms for the development of asthma and NERD by dysfunction of the physiological prostaglandin signalling in patients. Successful validation of prostaglandin signalling in this context will provide new therapeutic options for the treatment of related allergic lung inflammation.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors.
药理学简明指南 2023/24:G 蛋白偶联受体。
DOI:
10.1111/bph.16177
发表时间:
2023
期刊:
British journal of pharmacology
影响因子:
7.3
作者:
[Alexander SPH]
通讯作者:
Alexander SPH
DOI:
10.1111/j.1749-6632.1994.tb52729.x
发表时间:
1994-11
期刊:
Annals of the New York Academy of Sciences
影响因子:
5.2
作者:
[S. Narumiya]
通讯作者:
S. Narumiya
Editorial-Special issue of the 7th European workshop on lipid mediators.
第七届欧洲脂质介质研讨会社论特刊。
DOI:
10.1016/j.prostaglandins.2020.106421
发表时间:
2020
期刊:
Prostaglandins & other lipid mediators
影响因子:
2.9
作者:
[Alhouayek M]
通讯作者:
Alhouayek M
DOI:
10.1111/imcb.12167
发表时间:
2018-11
期刊:
Immunology and cell biology
影响因子:
4
作者:
[Crittenden S, Cheyne A, Adams A, Forster T, Robb CT, Felton J, Ho GT, Ruckerl D, Rossi AG, Anderton SM, Ghazal P, Satsangi J, Howie SE, Yao C]
通讯作者:
Yao C
国内基金
海外基金
登录
查看更多内容
声致离子电流促进小胶质细胞M2极化阻断再生神经瘢痕退变免疫机制
-
批准号:82371973
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:孙迪
-
依托单位:
转运蛋白RCP调控巨噬细胞脂肪酸氧化参与系统性红斑狼疮发病的机制研究
-
批准号:82371798
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:叶俊娜
-
依托单位:
基于FCER1G基因介导免疫反应探讨迟发性聋与认知障碍相关性的机制研究
-
批准号:82371141
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:陈颖
-
依托单位:
CD27-CD28-CD8+T细胞调控儿童肝脏移植免疫耐受形成的作用和机制
-
批准号:82371791
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:刘永波
-
依托单位:
T细胞受体NRP1作为新型免疫检查点在去势抵抗性前列腺癌中的作用机制研究
-
批准号:32100631
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:刘飞
-
依托单位:
抑制FGF19/FGFR4信号通路促进肺鳞癌细胞焦亡及免疫增效的机制研究
-
批准号:32100565
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:李凡
-
依托单位:
C9ORF72-SMCR8复合物在小胶质细胞中的功能及其介导的炎症反应
-
批准号:32070743
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:杨玫
-
依托单位:
间充质干细胞通过CD73/CD39/腺苷-PI3K/Akt-Nrf2信号轴调节CD4+IL-10+IFN-γ+T细胞分化减弱GVHD机制研究
-
批准号:32070781
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:栾希英
-
依托单位:
自噬基因Epg5在诺如病毒感染过程中的作用
-
批准号:32070745
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:路群
-
依托单位:
MET通过MTOR介导的自噬调节肝癌免疫原性和治疗抗性的作用及机制研究
-
批准号:31970696
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:黄星
-
依托单位: